Report cover image

Thalassemia Treatment Market by Type (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Iron Chelation), Indication Type (Alpha Thalassemia, Beta Thalassemia), End-Users - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 183 Pages
SKU # IRE18451026

Description

Thalassemia Treatment Market by Type (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Iron Chelation), Indication Type (Alpha Thalassemia, Beta Thalassemia), End-Users - Global Forecast 2024-2030


The Thalassemia Treatment Market size was estimated at USD 6.38 billion in 2023 and expected to reach USD 7.06 billion in 2024, at a CAGR 12.31% to reach USD 14.38 billion by 2030.

Global Thalassemia Treatment Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Thalassemia Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Thalassemia Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Thalassemia Treatment Market, highlighting leading vendors and their innovative profiles. These include ApoPharma Inc., Bellicum Pharmaceuticals, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics AG, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd., GL Pharma, Grifols International SA, Ionis Pharmaceuticals, Inc., La Jolla Pharmaceutical Company, Lonza Group AG, Macsen Laboratories, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Pharmascience Inc., Rajasthan Antibiotics Ltd, Sangamo Therapeutics, Inc., Sanofi S.A., Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Thalassemia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Blood Transfusion
Bone Marrow & Stem Cell Transplant
Iron Chelation
Luspatercept
Indication Type
Alpha Thalassemia
Beta Thalassemia
End-Users
Ambulatory Surgical Centers
Hospitals
Specialty Clinics
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Thalassemia Treatment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Thalassemia Treatment Market?
3. What are the technology trends and regulatory frameworks in the Thalassemia Treatment Market?
4. What is the market share of the leading vendors in the Thalassemia Treatment Market?
5. Which modes and strategic moves are suitable for entering the Thalassemia Treatment Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

183 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Thalassemia Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of thalassemia disorders among population
5.1.1.2. Awareness related to early diagnosis and treating thalassemia
5.1.1.3. Growing emphasis on genomic research
5.1.2. Restraints
5.1.2.1. High cost associated with thalassemia treatments
5.1.3. Opportunities
5.1.3.1. Rising number of approvals for novel thalassemia treatments
5.1.3.2. Increasing healthcare infrastructure spendings across economies
5.1.4. Challenges
5.1.4.1. Possible complications associated with thalassemia therapies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Thalassemia Treatment Market, by Type
6.1. Introduction
6.2. Blood Transfusion
6.3. Bone Marrow & Stem Cell Transplant
6.4. Iron Chelation
6.5. Luspatercept
7. Thalassemia Treatment Market, by Indication Type
7.1. Introduction
7.2. Alpha Thalassemia
7.3. Beta Thalassemia
8. Thalassemia Treatment Market, by End-Users
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Specialty Clinics
9. Americas Thalassemia Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Thalassemia Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Thalassemia Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. ApoPharma Inc.
13.1.2. Bellicum Pharmaceuticals, Inc.
13.1.3. bluebird bio, Inc.
13.1.4. Bristol-Myers Squibb Company
13.1.5. CRISPR Therapeutics AG
13.1.6. Editas Medicine Inc.
13.1.7. Errant Gene Therapeutics LLC
13.1.8. Gamida Cell Ltd.
13.1.9. GL Pharma
13.1.10. Grifols International SA
13.1.11. Ionis Pharmaceuticals, Inc.
13.1.12. La Jolla Pharmaceutical Company
13.1.13. Lonza Group AG
13.1.14. Macsen Laboratories
13.1.15. Merck & Co., Inc.
13.1.16. Novartis AG
13.1.17. Novo Nordisk A/S
13.1.18. Pfizer, Inc.
13.1.19. Pharmascience Inc.
13.1.20. Rajasthan Antibiotics Ltd
13.1.21. Sangamo Therapeutics, Inc.
13.1.22. Sanofi S.A.
13.1.23. Taj Pharmaceuticals Limited
13.1.24. Teva Pharmaceutical Industries Ltd.
13.1.25. Vertex Pharmaceuticals Incorporated
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. THALASSEMIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. THALASSEMIA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. THALASSEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. THALASSEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. THALASSEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. THALASSEMIA TREATMENT MARKET DYNAMICS
FIGURE 7. THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
FIGURE 10. THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. THALASSEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. THALASSEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us